跳至主要内容
临床试验/NCT03512392
NCT03512392已完成不适用

Role of Active Deresuscitation After Resuscitation- 2: a Pilot Randomised Controlled Trial of Conservative Fluid Management Versus Usual Care in Critical Illness

Belfast Health and Social Care Trust10 个研究点 分布在 1 个国家目标入组 180 人开始时间: 2018年4月10日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
180
试验地点
10
主要终点
Day 3 fluid balance

研究概览

简要总结

RADAR-2 will be a randomised, open-label, allocation concealed, pilot trial of conservative fluid administration and deresuscitation compared with usual care in patients who are critically ill.

详细描述

The optimal approach to fluid balance in critically ill patients is uncertain. A recent systematic review found low quality evidence in favour of a conservative fluid or deresuscitative approach (active removal of accumulated fluid using diuretics and/or renal replacement therapy) compared with a liberal strategy or usual care. The RADAR-2 pilot randomised trial will compare conservative fluid and deresuscitation with usual care in patients who are mechanically ventilated in an intensive care unit. The main hypothesis is that in critically ill patients, a post-resuscitation fluid strategy comprising conservative fluid administration and active deresuscitation reduces net fluid balance, is safe and improves clinical outcomes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

盲法说明

Group assignment and early (up to 28 day) data will be locked and unavailable to investigators undertaking 6-month follow up.

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Invasive mechanical ventilation
  • Treating ICU doctor expects patient to require treatment in an ICU beyond the next calendar day
  • Between 24 and 48 hours from ICU admission at the time of randomisation

排除标准

  • Age < 16 years
  • Body weight <40kg (measured or estimated)
  • Diabetic ketoacidosis or Hyperosmolar hyperglycaemic state
  • Non-traumatic subarachnoid haemorrhage
  • Acute cardiac failure or cardiogenic shock
  • End-stage renal failure (on dialysis)
  • Known to be pregnant
  • Suspected or proven active diabetes insipidus (DDAVP within 24 hours)
  • Not expected to survive for 72 hours
  • Active 'Do not attempt resuscitation' order
  • Refusal of consent
  • Inability of personal consultee to understand written or verbal information and for whom no interpreter is available
  • Known allergy to one or more of the study drugs
  • Inability to measure fluid balance

结局指标

主要结局

Day 3 fluid balance

时间窗: From beginning of day 2 to the beginning of study day 3.

Change in fluid balance (mL) between the beginning of study day 2 and the beginning of study day 3.

次要结局

  • Incidence of reported adverse events(Up to study day 5)
  • Mortality(28 and 180 days)
  • Length of ICU stay(28 days)
  • Acute kidney injury(Up to day 5.)
  • Cumulative fluid balance(Up to the beginning of days 3 and 5, and at ICU discharge (estimated median day 7))
  • Incidence of significant protocol violations(Up to study day 5)
  • Change in Sequential Organ Function Assessment scores(From baseline until day 3 and day 5)
  • Cognitive function(180 days)
  • Duration of mechanical ventilation(28 days)
  • Health-related quality of life(180 days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (10)

Loading locations...

相似试验